110 results
6-K
EX-99.3
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
of a legal entity, must provide evidence of their identity in order to be granted access to the meeting. In addition, the representatives of legal entities … to access, the right to rectify and the right to object to processing, which are further outlined in the section ‘Your rights as a data subject
6-K
EX-99.7
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
billion upfront payment from Gilead Sciences, and (ii) Gilead Sciences gained exclusive access and certain rights to the Company’s innovative portfolio … , and allows access to Gilead’s chemistry and development expertise, its commercial infrastructure and operations, and its speed to the relevant
6-K
EX-99.2
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
and building our pipeline through strategic partnerships and M&A. To achieve our ambitious goals, we evaluate and access external innovation. We … factors for large-scale capacity and broad patient access globally. Limitations of current CAR-Ts Patients with high unmet medical needs Medical need
6-K
EX-99.1
vlz0dz7zzerajif605
23 Feb 24
Galapagos announces full year 2023 results and outlook for 2024
6:41am
6-K
EX-99.1
kn2ia
6 Feb 24
Galapagos completes transaction to transfer Jyseleca® business to Alfasigma
6:00am
S-8
EX-99.1
n4b5ll5c
4 Dec 23
Registration of securities for employees
5:16pm
S-8
EX-99.2
eyxbur4cvs9
4 Dec 23
Registration of securities for employees
5:16pm
S-8
EX-99.3
vpikkc2txaa
4 Dec 23
Registration of securities for employees
5:16pm
6-K
EX-99.1
lafxn3s khduzdkw03
3 Nov 23
Galapagos reports third quarter 2023 results and releases new encouraging data from CAR-T studies for presentation at ASH 2023
8:26am
6-K
EX-99.2
auq9j
4 Aug 23
Galapagos announces first half-year 2023 financial results
4:05pm
6-K
EX-99.1
18agclq xo05z7vus
4 Aug 23
Galapagos announces first half-year 2023 financial results
4:05pm
6-K
EX-99.1
62urc5ha55gwqbv g6b
13 Jun 23
Galapagos appoints Dr. Susanne Schaffert as non-executive independent Director to its Board
7:53am
6-K
EX-99.1
68lmr
5 May 23
Galapagos announces first quarter 2023 financial results
4:05pm
6-K
EX-99.1
3hxs5ru7 h0
31 Mar 23
Current report (foreign)
6:05am
6-K
EX-99.1
bfv3v84r qw
13 Dec 22
Galapagos and CellPoint presented encouraging initial data at ASH 2022 for GLPG5101, a CD19 CAR-T candidate manufactured at point-of-care
7:49am
6-K
EX-99.1
m00l6i
7 Nov 22
Galapagos announces strategy to accelerate innovation and reports strong third quarter 2022 results
6:08am